These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25799264)

  • 1. Design and Synthesis of New α-Naphthoflavones as Cytochrome P450 (CYP) 1B1 Inhibitors To Overcome Docetaxel-Resistance Associated with CYP1B1 Overexpression.
    Cui J; Meng Q; Zhang X; Cui Q; Zhou W; Li S
    J Med Chem; 2015 Apr; 58(8):3534-47. PubMed ID: 25799264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α-naphthoflavone-derived cytochrome P450 (CYP)1B1 degraders specific for sensitizing CYP1B1-mediated drug resistance to prostate cancer DU145: Structure activity relationship.
    Chen P; Wang S; Cao C; Ye W; Wang M; Zhou C; Chen W; Zhang X; Zhang K; Zhou W
    Bioorg Chem; 2021 Nov; 116():105295. PubMed ID: 34455300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationship studies of α-naphthoflavone derivatives as CYP1B1 inhibitors.
    Dong J; Wang Z; Cui J; Meng Q; Li S
    Eur J Med Chem; 2020 Feb; 187():111938. PubMed ID: 31830634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of α-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation.
    Zhou L; Chen W; Cao C; Shi Y; Ye W; Hu J; Wang L; Zhou W
    Eur J Med Chem; 2020 Mar; 189():112028. PubMed ID: 31945665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of heterocycle-containing α-naphthoflavone derivatives as water-soluble, highly potent and selective CYP1B1 inhibitors.
    Dong J; Huang G; Cui Q; Meng Q; Li S; Cui J
    Eur J Med Chem; 2021 Jan; 209():112895. PubMed ID: 33069055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of selective CYP1B1 inhibitor via dearomatization of α-naphthoflavone.
    Kubo M; Yamamoto K; Itoh T
    Bioorg Med Chem; 2019 Jan; 27(2):285-304. PubMed ID: 30553624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycyrrhiza glabra extract and quercetin reverses cisplatin resistance in triple-negative MDA-MB-468 breast cancer cells via inhibition of cytochrome P450 1B1 enzyme.
    Sharma R; Gatchie L; Williams IS; Jain SK; Vishwakarma RA; Chaudhuri B; Bharate SB
    Bioorg Med Chem Lett; 2017 Dec; 27(24):5400-5403. PubMed ID: 29150398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming Taxol-resistance in A549 cells: A comprehensive strategy of targeting P-gp transporter, AKT/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin.
    Lin H; Hu B; He X; Mao J; Wang Y; Wang J; Zhang T; Zheng J; Peng Y; Zhang F
    Biochem Pharmacol; 2020 Jan; 171():113733. PubMed ID: 31783010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspective of structural flexibility on selective inhibition towards CYP1B1 over CYP1A1 by α-naphthoflavone analogs.
    Wang Y; Hu B; Zhang Y; Wang D; Luo Z; Wang J; Zhang F
    Phys Chem Chem Phys; 2021 Sep; 23(36):20230-20246. PubMed ID: 34474468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma.
    Chang I; Mitsui Y; Fukuhara S; Gill A; Wong DK; Yamamura S; Shahryari V; Tabatabai ZL; Dahiya R; Shin DM; Tanaka Y
    Oncotarget; 2015 Apr; 6(10):7774-87. PubMed ID: 25860934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.
    Williams IS; Joshi P; Gatchie L; Sharma M; Satti NK; Vishwakarma RA; Chaudhuri B; Bharate SB
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3683-3687. PubMed ID: 28711350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Cytochrome P450 (CYP) 1B1 Enzyme with Four Series of A-Ring Substituted Estrane Derivatives: Design, Synthesis, Inhibitory Activity, and Selectivity.
    Dutour R; Roy J; Cortés-Benítez F; Maltais R; Poirier D
    J Med Chem; 2018 Oct; 61(20):9229-9245. PubMed ID: 30216063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Synthesis of Chalcones as Anticancer Prodrugs and their Bioactivation in CYP1 Expressing Breast Cancer Cells.
    Ruparelia KC; Zeka K; Ijaz T; Ankrett DN; Wilsher NE; Butler PC; Tan HL; Lodhi S; Bhambra AS; Potter GA; Arroo RRJ; Beresford KJM
    Med Chem; 2018; 14(4):322-332. PubMed ID: 29332599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of human CYP1 enzymes by a classical inhibitor α-naphthoflavone and a novel inhibitor N-(3, 5-dichlorophenyl)cyclopropanecarboxamide: An in vitro and in silico study.
    Juvonen RO; Jokinen EM; Javaid A; Lehtonen M; Raunio H; Pentikäinen OT
    Chem Biol Drug Des; 2020 May; 95(5):520-533. PubMed ID: 32060993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP enzymes, expressed within live human suspension cells, are superior to widely-used microsomal enzymes in identifying potent CYP1A1/CYP1B1 inhibitors: Identification of quinazolinones as CYP1A1/CYP1B1 inhibitors that efficiently reverse B[a]P toxicity and cisplatin resistance.
    Sonawane VR; Siddique MUM; Gatchie L; Williams IS; Bharate SB; Jayaprakash V; Sinha BN; Chaudhuri B
    Eur J Pharm Sci; 2019 Apr; 131():177-194. PubMed ID: 30776468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme.
    Bournique B; Lemarié A
    Drug Metab Dispos; 2002 Nov; 30(11):1149-52. PubMed ID: 12386117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of CYP1B1-specific candidate inhibitors using combination of in silico screening, integrated knowledge-based filtering, and molecular dynamics simulations.
    Kumar R; Gupta D
    Chem Biol Drug Des; 2016 Nov; 88(5):730-739. PubMed ID: 27300691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biphenyl urea derivatives as selective CYP1B1 inhibitors.
    Mohd Siddique MU; McCann GJ; Sonawane V; Horley N; Williams IS; Joshi P; Bharate SB; Jayaprakash V; Sinha BN; Chaudhuri B
    Org Biomol Chem; 2016 Sep; 14(38):8931-8936. PubMed ID: 27714268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance.
    McFadyen MC; McLeod HL; Jackson FC; Melvin WT; Doehmer J; Murray GI
    Biochem Pharmacol; 2001 Jul; 62(2):207-12. PubMed ID: 11389879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, Synthesis and Binding Affinity Evaluation of Cytochrome P450 1B1 Targeted Chelators.
    Chen D; Fan Q; Xu T; Dong J; Cui J; Wang Z; Wang J; Meng Q; Li S
    Anticancer Agents Med Chem; 2022; 22(2):261-269. PubMed ID: 33820523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.